TAG challenges HIV vaccine cuts as Robert F. Kennedy fires entire CDC vaccine expert advisory panel
6 June 2025. Related: Early access, Treatment access, Activism & advocacy, Research studies.
Treatment access
Gates Foundation commits to providing lenacapavir as PrEP next year
3 June 2025. Related: Early access, Treatment access.
Featured Latest news on the US crisis and its impact on global health
1 June 2025. Related: Journal scan, Special reports, Treatment access, Activism & advocacy.
HIV activists in the US call for action in JID and Zachie Achmat brings South African perspective in the Lancet
26 May 2025. Related: Journal scan, Treatment access, Activism & advocacy.
Combining injectable lenacapavir and cabotegravir-LA
23 May 2025. Related: Journal scan, Antiretrovirals, Treatment strategies, Treatment access.
Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement
22 May 2025. Related: Treatment access, Activism & advocacy, Research studies.
Impact of US funding cuts in Malawi and South Africa: ITPC community report
20 May 2025. Related: Treatment access, On the web.
Featured Reduced dosing: a possible crisis response to ART stockouts and closed clinics
5 May 2025. Related: Special reports, Antiretrovirals, Treatment strategies, Treatment access.
Closed clinics and limited ART in Zimbabwe, PEPFAR and UNAIDS news
4 May 2025. Related: Treatment access, Activism & advocacy.
Lenacapavir EAP in the UK closed to new referrals: NHS England and Gilead fail to agree a price after more than two years
20 April 2025. Related: Antiretrovirals, Treatment access, Drug resistance, BHIVA news.
Changes to US policy jeopardises the lives of 500,000 children living with HIV by 2030
8 April 2025. Related: Treatment access.
Lancet HIV recognises Transgender Day of Visibility and the importance of gender-affirming hormones in HIV care
3 April 2025. Related: Journal scan, Special reports, Treatment access.
Cuts in aid: up to 10 million new HIV infections and almost 3 million related deaths by 2030
28 March 2025. Related: Journal scan, Treatment access.
Webinar on stopping ART if your clinic is closed: practical facts on safety and risk
24 March 2025. Related: Special reports, Treatment strategies, Treatment access, On the web.
Global update: 90-day review ended early and cancelled 10,000 grants, millions of people will suffer
1 March 2025. Related: Special reports, Treatment access.
Responses to the UK government slashing international aid by 40%
26 February 2025. Related: Treatment access, Activism & advocacy.
Deleted words from official documents: LGBTQ, diversity, inclusion, transgender
26 February 2025. Related: Treatment access, Activism & advocacy.
Country update from Nigeria: current impact on HIV services
22 February 2025. Related: Special reports, Treatment access.
Impact of US elections and executive orders on global health: waiver covers PEPFAR with restrictions
7 February 2025. Related: Special reports, Treatment access, Activism & advocacy.
IAS public letter: Why HIV could be poised for a monumental comeback
6 February 2025. Related: Treatment access, On the web.
US issues temporary waiver to re-enable PEPFAR
29 January 2025. Related: Treatment access.
IAS statement: PEPFAR freeze threatens millions of lives
25 January 2025. Related: Treatment access.
Trump bans travel for US government scientists, presentations restricted, language bans, documents disappearing
23 January 2025. Related: Treatment access, Activism & advocacy, Research studies.
Lenacapavir submitted to the US FDA with an indication for HIV PrEP
1 January 2025. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.
Management of drug resistance to integrase inhibitors: results from an international perinatal virtual clinic
1 November 2024. Related: Treatment access, Paediatric care, Drug resistance.
Helsinki Declaration: 2024 edition upholds ethical access to treatment
23 October 2024. Related: Treatment access, HIV prevention and transmission.
HIVR4P 2024: Introduction
14 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
Urgency of planning broad vaccine-like access to lenacapavir PrEP globally
13 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
HIVR4P 2024: Context of PrEP in Latin America
7 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
Gilead announces plans to support generic lenacapavir for low-income countries
2 October 2024. Related: Treatment access.
NICE defers decision on CAB-LA as PrEP needing more information
27 September 2024. Related: Treatment access, HIV prevention and transmission.
UNAIDS reports debt crisis obstructs HIV response
19 September 2024. Related: Treatment access, Other news.
AIDS 2024: Including people living with HIV in non-HIV research
11 September 2024. Related: Conference reports, Treatment access, Cancer and HIV, Activism & advocacy.
Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV
26 July 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
CHAI six-monthly market report (July 2024)
16 July 2024. Related: Treatment access, On the web.
Uganda Court rejects appeal against the LGBTQ+ hate law
5 April 2024. Related: Special reports, Treatment access.
CROI 2024: Opening lecture calls for scientists to speak up for LGBTQ+ rights in Uganda
24 March 2024. Related: Conference reports, Treatment access, Women's health, Pregnancy, Vaccines and microbicides.
CROI 2024: Promising results from first study of long-acting treatment in Africa
10 March 2024. Related: Conference reports, Antiretrovirals, Treatment access.
Uganda hate law blocks HIV research: join 300 leading researchers in sign-on protest
4 January 2024. Related: Special reports, Treatment access, Activism & advocacy, Research studies.
First-line ART drops below US $45 a year for low-income countries
1 December 2023. Related: Antiretrovirals, Treatment access.
CHAI 2023 market report: decline in HIV funding threatens 20 years of progress
1 December 2023. Related: Treatment access.
Implications of restrictions on reproductive rights for HIV care in the USA and beyond
6 April 2023. Related: Conference reports, Treatment access, Women's health, Pregnancy.
CHAI 2022 report on global access to ART
1 December 2022. Related: Treatment access.
ViiV licenses long-acting cabotegravir (CAB-LA) for generic access
1 June 2022. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.
Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits
2 May 2022. Related: Antiretrovirals, Treatment access.
NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales
30 November 2021. Related: Antiretrovirals, Treatment access.
Darunavir/ritonavir price now US $210 for global access
17 September 2021. Related: Treatment access.
UK government to cut international HIV support to UNAIDS by 80%
3 May 2021. Related: Treatment access.
New formulation of dolutegravir will make modern ART available for babies and young children at less than $120 a year
9 December 2020. Related: Antiretrovirals, Treatment access, Paediatric care.
Dolutegravir/lamivudine FDC recommended by NHS England
12 March 2020. Related: Treatment access.
US government claims patent infringement by Gilead Sciences over use of F/TAF and FTC/TDF as PrEP
15 November 2019. Related: Treatment access, HIV prevention and transmission.
UK contributes £1.4 billion towards Global Fund for 2020 to 2022
18 October 2019. Related: Treatment access.
Global Fund raises US$14 billion for 2020 to 2022
18 October 2019. Related: Treatment access.
Scotland approves dual therapy with dolutegravir/lamivudine (Dovato)
30 September 2019. Related: Antiretrovirals, Treatment access.
UK HIV organisations call for urgent review of crisis in sexual health funding
30 September 2019. Related: Treatment access, Other news.
Two pints of lager and a packet of PrEP please: London price for HIV PrEP drops to £17.50
19 June 2019. Related: Treatment access, HIV prevention and transmission.
Activists challenge block to generic PrEP and current US price of TDF/FTC
19 June 2019. Related: Treatment access, HIV prevention and transmission.
BHIVA preconference: U=U and HIV and immigration detention
30 April 2019. Related: Conference reports, Treatment access, HIV prevention and transmission.
Civil society organisations push for a target of $18 billion for the Global Fund’s sixth replenishment
20 February 2019. Related: Treatment access.
BMJ survey reports lack of NHS planning for Brexit: impact on drug supplies unknown
21 January 2019. Related: Treatment access.
BASHH, BHIVA, HIVPA and NHIVNA statement on a no-deal Brexit
21 January 2019. Related: Treatment access.
UK-CAB statement on Brexit, HIV and access to medicines
21 January 2019. Related: Treatment access.
Model predicts benefit of dolutegravir for all in sub-Saharan Africa outweighs risk
21 January 2019. Related: Treatment access.
Activists demand $1 a day access to bedaquiline for MDR TB
13 November 2018. Related: Treatment access, TB coinfection.
UK government funding cuts leave sexual health and HIV care at breaking point
19 October 2018. Related: Treatment access.